These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 31375606)
1. Prevention of relapses with levamisole as adjuvant therapy in children with a first episode of idiopathic nephrotic syndrome: study protocol for a double blind, randomised placebo-controlled trial (the LEARNS study). Veltkamp F; Khan DH; Reefman C; Veissi S; van Oers HA; Levtchenko E; Mathôt RAA; Florquin S; van Wijk JAE; Schreuder MF; Haverman L; Bouts AHM BMJ Open; 2019 Aug; 9(8):e027011. PubMed ID: 31375606 [TBL] [Abstract][Full Text] [Related]
2. REducing STEroids in Relapsing Nephrotic syndrome: the RESTERN study- protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study. Schijvens AM; Dorresteijn EM; Roeleveld N; Ter Heine R; van Wijk JAE; Bouts AHM; Keijzer-Veen MG; van de Kar NCAJ; van den Heuvel LPWJ; Schreuder MF BMJ Open; 2017 Sep; 7(9):e018148. PubMed ID: 28963315 [TBL] [Abstract][Full Text] [Related]
3. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT. Webb NJ; Woolley RL; Lambe T; Frew E; Brettell EA; Barsoum EN; Trompeter RS; Cummins C; Wheatley K; Ives NJ Health Technol Assess; 2019 May; 23(26):1-108. PubMed ID: 31156083 [TBL] [Abstract][Full Text] [Related]
4. Daily low-dose prednisolone to prevent relapse of steroid-sensitive nephrotic syndrome in children with an upper respiratory tract infection: PREDNOS2 RCT. Christian MT; Webb NJ; Woolley RL; Afentou N; Mehta S; Frew E; Brettell EA; Khan AR; Milford DV; Bockenhauer D; Saleem MA; Hall AS; Koziell A; Maxwell H; Hegde S; Finlay ER; Gilbert RD; Jones C; McKeever K; Cook W; Ives N Health Technol Assess; 2022 Jan; 26(3):1-94. PubMed ID: 35060851 [TBL] [Abstract][Full Text] [Related]
5. Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation. Webb NJA; Woolley RL; Lambe T; Frew E; Brettell EA; Barsoum EN; Trompeter RS; Cummins C; Deeks JJ; Wheatley K; Ives NJ; BMJ; 2019 May; 365():l1800. PubMed ID: 31335316 [TBL] [Abstract][Full Text] [Related]
6. A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome. Gruppen MP; Bouts AH; Jansen-van der Weide MC; Merkus MP; Zurowska A; Maternik M; Massella L; Emma F; Niaudet P; Cornelissen EAM; Schurmans T; Raes A; van de Walle J; van Dyck M; Gulati A; Bagga A; Davin JC; Kidney Int; 2018 Feb; 93(2):510-518. PubMed ID: 29054532 [TBL] [Abstract][Full Text] [Related]
7. An open label non-inferiority randomized controlled trial evaluated alternate day prednisolone given daily during infections vs. levamisole in frequently relapsing nephrotic syndrome. Sinha A; Devi KG; Kalra S; Mani K; Hari P; Bagga A Kidney Int; 2024 May; 105(5):1113-1123. PubMed ID: 38360110 [TBL] [Abstract][Full Text] [Related]
8. Initial treatment of steroid-sensitive idiopathic nephrotic syndrome in children with mycophenolate mofetil Ehren R; Benz MR; Doetsch J; Fichtner A; Gellermann J; Haffner D; Höcker B; Hoyer PF; Kästner B; Kemper MJ; Konrad M; Luntz S; Querfeld U; Sander A; Toenshoff B; Weber LT; BMJ Open; 2018 Oct; 8(10):e024882. PubMed ID: 30309995 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial. Sinha A; Puraswani M; Kalaivani M; Goyal P; Hari P; Bagga A Kidney Int; 2019 Jan; 95(1):210-218. PubMed ID: 30497684 [TBL] [Abstract][Full Text] [Related]
10. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07). Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824 [TBL] [Abstract][Full Text] [Related]
11. Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise? Davin JC; Merkus MP Pediatr Nephrol; 2005 Jan; 20(1):10-4. PubMed ID: 15378419 [TBL] [Abstract][Full Text] [Related]
12. Levamisole in steroid-sensitive nephrotic syndrome children with steroid-dependency and/or frequent relapses. Fu LS; Chi CS Acta Paediatr Taiwan; 2000; 41(2):80-4. PubMed ID: 10927944 [TBL] [Abstract][Full Text] [Related]
13. Daily compared with alternate-day levamisole in pediatric nephrotic syndrome: an open-label randomized controlled study. Banerjee S; Sengupta J; Sinha R; Chatterjee S; Sarkar S; Akhtar S; Saha R; Pahari A Pediatr Nephrol; 2024 Oct; 39(10):2969-2977. PubMed ID: 38822220 [TBL] [Abstract][Full Text] [Related]
15. Levamisole in steroid-sensitive nephrotic syndrome children with frequent relapses and/or steroid dependency: comparison of daily and every-other-day usage. Fu LS; Shien CY; Chi CS Nephron Clin Pract; 2004; 97(4):c137-41. PubMed ID: 15331936 [TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Bagga A; Hari P; Moudgil A; Jordan SC Am J Kidney Dis; 2003 Dec; 42(6):1114-20. PubMed ID: 14655181 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of levamisole in children with frequently relapsing and steroid-dependent nephrotic syndrome. Ekambaram S; Mahalingam V; Nageswaran P; Udani A; Geminiganesan S; Priyadarshini S Indian Pediatr; 2014 May; 51(5):371-3. PubMed ID: 24953577 [TBL] [Abstract][Full Text] [Related]
19. Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology. Lancet; 1991 Jun; 337(8757):1555-7. PubMed ID: 1675705 [TBL] [Abstract][Full Text] [Related]